SERB Pharmaceuticals, a global specialty pharmaceutical company, announced that Aurlumyn (iloprost) Injection, the first FDA-approved treatment for severe frostbite in adults to reduce the risk of digit amputations, is now commercially available in the US.
Dr. Jennifer Dow, emergency medicine physician at Alaska Regional Hospital and medical director for the Alaska Region of the National Park Service, said, “This marks a significant milestone in the field of frostbite treatment in the United States and represents a new era of hope for patients at risk of digit amputations. Frostbite can be a debilitating condition that can lead to devastating consequences for patients. We hope Aurlumyn will revolutionize the standard of care and provide physicians with an essential tool to treat this condition and reduce the risk of amputations.”
Thomas Kolaras, executive vice president and U.S. chief commercial officer, said: “We are proud to make Aurlumyn (pronounced Or-Loo-Min) available to hospitals, first responders and military customers in the U.S. This treatment empowers healthcare professionals to act decisively in critical moments, delivering hope and effective care to those at risk of life-altering complications.”
Studies show that thousands of people in the U.S. are hospitalized with frostbite yearly. This debilitating condition, most often affecting winter sports enthusiasts, military personnel, and outdoor workers, can lead to digit or limb necrosis requiring amputation.
The most recent Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Frostbite “strongly recommends” considering Aurlumyn as a first-line therapy for Grades 3 and 4 frostbite <48 hours after thawing and possibly for up to 72 hours.
Learn more at aurlumyn.com
